Page 7 - ACV Journal DECEMBER 2015
P. 7
WERE YOU EXPECTING THIS?
Treating mastitis with Metacam®20 also improved fertility1
We’ve come to expect therapeutic efficacy and productivity benefits from Metacam®20. What we
didn’t expect, until recently, were fertility benefits too. Our new large-scale (n = over 500) landmark
study found that the addition of Metacam®20 to standard antibiotic therapy for mastitis was
associated with a greater first-service conception rate, fewer inseminations and a higher
probability of pregnancy by 120 days post-calving.1
Expectations of Metacam®20 treatment are changing accordingly. Are yours?
Longer reproductive life
Reference 1. McDougall et al. Addition of meloxicam to the treatment of clinical mastitis improves subsequent reproductive performance. Submitted for publication. Further information available from Boehringer Ingelheim.
New Zealand: Boehringer Ingelheim (NZ) Limited, Animal Health Division, Level 1, Unit 9, 42 Ormiston Road, East Tamaki, Manukau 2016. Toll free: 0800 802 461. Restricted Veterinary Medicine. Access is only through a veterinary
authorisation. Australia: Boehringer Ingelheim Pty Limited ABN 52 000 452 308. Animal Health Division, 78 Waterloo Road, North Ryde NSW 2113. Toll free: 1800 038 037. Metacam®20 is a trademark of Boehringer Ingelheim
Vetmedica GmbH, 55216 Ingelheim am Rhein, Germany. BIV/8460
